Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer

Cancer Immunology, Immunotherapy

Volumn 64, Issue 1, 2015, Pages 51-59

  Kimura, Hideki ^a,c   Matsui, Yukiko ^a   Ishikawa, Aki ^b   Nakajima, Takahiro ^b   Yoshino, Mitsuru ^b   Sakairi, Yuichi ^b  

^a CHIBA CANCER CENTER   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Center for Rheumatic Diseases   (Japan)

Author keywords

Adjuvant therapy; Dendritic cell; Immunotherapy; Lung cancer; Lymph node; Phase III study

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB;

ACTIVATED KILLER T CELL; ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CHILL; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INDUCTION CHEMOTHERAPY; KILLER CELL; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SHIVERING; TREATMENT OUTCOME; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; AGED; CANCER GRADING; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; FOLLOW UP; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84939779991     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1613-0     Document Type: Article

References (37)

1. Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892
2. Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12:323–334
3. O’Flaherty JD, Gray S, Richard D et al (2012) Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer 76:19–25
4. Gorges TM, Pantel K (2013) Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol Immunother 62:931–939. doi:10.1007/s00262-012-1387-1
5. Berghmans T, Paesmans M, Meert AP et al (2005) Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 49:13–23
6. Bennouna J, Senellart H, Hiret S et al (2011) Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial. Lung Cancer 74:30–34
7. Felip E, Martinez-Marti A, Martinez P et al (2013) Adjuvant treatment of resected non-small cell lung cancer: state of the art and new potential developments. Curr Opin Oncol 25:115–120
8. Chen G, Emens LA (2013) Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother 62:203–216. doi:10.1007/s00262-012-1388-0
9. Kimura H, Dobrenkov K, Iida T et al (2005) Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells. Anticancer Res 25:85–94
10. Kimura H, Yasufuku K, Ando S et al (2007) Indications for mediastinoscopy and comparison of lymph node dissections in candidates for lung cancer surgery. Lung Cancer 56:349–355
11. Burdett S, Stewart LA, Rydzewska L (2006) A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 1:611–621
12. Strauss GM, Herndon JE, Maddaus MA et al (2008) Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 26:5043–5051
13. Arriagada R, Bergman B, Dunant A et al (2004) International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360
14. Tango T (2003) Medical Statistics Series 5, Randomized studies: Design and Statistical Analyses. Asakura Shoten, Tokyo, pp 59–62
15. Kimura H, Yamaguchi Y (1997) A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 80:42–49
16. Kimura H, Iizasa T, Ishikawa A et al (2008) Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients. Anticancer Res 28:1229–1238
17. Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveilance to tumor escape. Nat Immunol 3:991–998
18. Kim R, Emi M, Tanabe K et al (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121:1–14
19. Schreiber RD, Old LJ, Smyth MJ et al (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570
20. Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834–846
21. Almog N (2010) Molecular mechanisms underlying tumor dormancy. Cancer Lett 294:139–146
22. Enderling H, Hahnfeldt P, Hlatky L et al (2012) Systems biology of tumor dormancy: linking biology and mathematics on multiple scales to improve cancer therapy. Cancer Res 72:2172–2175
23. Gutkin DW, Shurin MR (2014) Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol Immunother 63:45–57. doi:10.1007/s00262-013-1480-0
24. Pardoll D (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807–839
25. Gajewski TF, Meng Y, Blank C et al (2006) Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213:131–145
26. Rabinovich GA, Gabrilovich D, Sotomayor EM et al (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267–296
27. Becker JC, Andersen MH, Schrama D et al (2013) Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother 62:1137–1148. doi:10.1007/s00262-013-1434-6
28. Rosenberg SA, Yang JC, Restifo NP et al (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915
29. Dudley ME, Wunderlich JR, Yang JC et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346–2357
30. Gattinoni L, Powell DJ Jr, Rosenberg SA et al (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6:383–393
31. Kuwai T, Nakamura T, Kim SJ et al (2008) Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors. Am J Pathol 172:358–366
32. Maass G, Schmidt W, Berger M et al (1995) Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 92:5540–5544
33. Schweighoffer T, Schmidt W, Buschle M et al (1996) Depletion of naive T cells of the peripheral lymph nodes abrogates systemic antitumor protection conferred by IL-2 secreting cancer vaccines. Gene Ther 3:819–824
34. Adema GJ, Hartgers F, Verstraten R et al (1997) A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 387:713–717
35. Kimura H, Yamaguchi Y, Kadoyama C (1983) Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor. Jpn J Clin Oncol 13:3–13
36. Kadoyama C, Kimura H, Yamaguchi Y (1987) Inhibition of cytotoxicity to autologous tumor cells by the regional lymph node cells of patients with primary lung cancer. Jpn J Clin Oncol 17:29–39
37. Kimura H, Yamaguchi Y (1989) Cytotoxic activity of various LAK cells against autologous lung cancer, K-562 and Daudi cells. Jpn J Clin Oncol 19:222–228